Kornimate/medical-research-clean huggingface dataset:
energy balance and inflammation in obese adults bariatric surgery follow-up

Conditions: Obesity; Morbid Obesity; Metabolic Syndrome; Inflammation; Energy Balance

Summary: the prevalence of obesity is steadily growing in many parts of the world in order to reach epidemic proportions. changes in signaling pathways state of hunger and satiety contribute to the increase in obesity and metabolic syndrome. currently, the white adipose tissue, also is considered a secretory tissue by producing numerous adipokines involved in a chronic state of inflammation, which may interfere with the neuroendocrine regulation of energy balance that affect the weight loss process. the bariatric surgery is recommended as the most effective tool in the treatment and control of morbid obesity. the study population will consist of patients undergoing bariatric surgery of type roux-en-y gastric bypass. the study was performed in clinical hospital of the federal university of paraná (ufpr). this is a prospective cohort study with follow up of 6 and 24 months. the aim of this study is to assess the effects of weight loss after bariatric surgery associated anthropometric characteristic, metabolic changes (glucose, cholesterol profile,hepatic enzymes, fibroblast growth factor- 21(fgf-21), blood pressure), the profile of adipokines pro/anti-inflammatory (adiponectin, interleukin-6 (il-6),interleukin-10 (il-10), c reactive protein (crp), plasminogen activator inhibitor-1 (pai-1), tumor necrosis factor alpha (tnf-α), intercellular adhesion molecule-1 (icam-1), resistin, frizzled-related protein 5 (sfrp5) and neuroendocrine regulation of energy balance (leptin, neuropeptide y (npy) , alpha-melanocyte stimulating hormone (α-msh), melanin-concentrating hormone (mch) and agouti-related peptide (agrp), as well as the quality of life in obese adults.


Eligibility criteria:
inclusion criteria: * age range 20-59 years * bmi ≥ 40 kg/m2 * bmi ≥ 35 kg/m2 with comorbidity recognised by national institutes of health. exclusion criteria: * patients in use of insulin * patients in use of immunosuppressant * anti-inflammatory and/or immunosuppressant therapies * any malignancy * chronic kidney or liver disease * obesity caused by an endocrine disorder * patients with psychiatric disorders * smoker or alcohol dependence * patients with rheumatoid arthritis and/or autoimmune
the effect of chinese herbs to treat thyroid diseases with different iodine intake

Conditions: Thyroid Diseases

Summary: safe study of chinese herbs to treat thyroid diseases with different iodine

based on the previous studies, the research choose the patients with different iodine intake,and improve our original chinese herbs thyroid iii formula, in order to provide the patients the best individual treatment plan.

Eligibility criteria:
inclusion criteria: * patient with thyroid diseases exclusion criteria: * not meet the diagnostic criteria,women with pregnancy or lactation ,drug allergy ,need surgery
laparoscopic sleeve gastrectomy in severely obese adolescents: effects on metabolism

Conditions: Obesity; Surgery

Summary: severe obesity (so), defined as bmi≥95th percentile, has increased worldwide among adolescents. american studies estimated that 1.3-2.8% of 12-19-year-old individuals have a bmi \>40 kg/m2 or a bmi \>35 kg/m2 with at least one serious co-morbidity. the immediate and long-term risks associated with so in adolescents include cardiovascular and metabolic diseases, obstructive sleep apnoea and nonalcoholic fatty liver disease. however, the results of sleeve gastrectomy in adolescents are still uncertain. objective and hypotheses: investigators aimed to assess the long-term safety, efficacy, and cardiovascular risk changes of laparoscopic sleeve gastrectomy in adolescents with so. method: longitudinal retrospective study of 22 adolescents with so who underwent laparoscopic sleeve gastrectomy. clinical and metabolic variables immediately before surgery and after 6, 12, 18 and 24 months were assessed.


Eligibility criteria:
inclusion criteria: * ages of 14 and 19 * submitted to lsg between 2007 and 2014. * attended the child obesity clinic of the pediatric endocrinology department of the instituto da criança da universidade de são paulo (children's institute of university of são paulo). * received clinical and pharmacological treatment for at least 6 months before surgery and were followed by a multidisciplinary team including a pediatric endocrinologist, a nutritionist, a psychologist and a physical educator. * bmi \> 40 kg/m2 or bmi \> 35 kg/m2 with comorbidities and failed to achieve significant weight loss (10% of initial weight at 6 months) through clinical treatment. * both the patients and their guardians were informed about the risks and benefits of surgery and provided informed consent. exclusion criteria: * it was a retrospective study

Keywords: cardiovascular risk metabolic profile
the tilburg vasospasm study

Conditions: Brain Ischemia; Intracranial Vasospasm

Summary: in a prospective randomized controlled trial, the investigators aim to assess whether external lumbar drainage (eld) of csf is safe and reduces delayed cerebral ischemia and its sequelae in patients with an aneurysmal subarachnoid hemorrhage.

delayed cerebral ischemia (dci) is a frequent complication after an aneurysmal subarachnoid hemorrhage (sah). its pathophysiological mechanism remains unclear but a role for cerebral vasospasm and the presence of blood in the arachnoid space is likely. a wash out of blood and blood breakdown products in the cerebrospinal fluid (csf) could reduce the incidence of vasospasm and dci. we aim to assess whether external lumbar drainage (eld) of csf is safe and reduces secondary ischemia and its sequelae.

Eligibility criteria:
inclusion criteria: * spontaneous subarachnoid hemorrhage (sah) with aneurysmal pattern graded as a fisher grade iii or higher on cerebral ct-scan. * csf drainage by external lumbar catheter can start within 96 hours after the initial sah * the drainage can start prior to the treatment of the ruptured aneurysm * informed consent is signed by the patient or his representative exclusion criteria: * spontaneous sah with aneurysmal pattern graded as a fisher grade i or ii on ct and perimesencephalic hemorrhages * traumatic sah * symptomatic hydrocephalus on admission necessitating drainage (evd or eld) * the presence of a large intraventricular bloodclot in the third or fourth ventricle on ct * the presence of a mass lesion with significant cerebral midline shift * all patients whose neurological condition is too poor to allow clinical recognition of signs and symptoms of cerebral vasospasm. this includes all patients with a hunt and hess grade v who failed to improve after initial resuscitation * no informed consent * mycotic aneurysms

Keywords: subarachnoid hemorrhage delayed cerebral ischemia external lumbar drainage vasospasm
effects of stress ball use for patients undergoing local anesthesia in ambulatory surgery

Conditions: Anxiety

Summary: preoperative anxiety begins from the decision-making of surgery to entering the operating room and may intensify as the surgery date approaches. anxiety not only causes physiological effects but also psychological impacts, leading to negative outcomes for postoperative recovery. ambulatory surgeries often employ local anesthesia, where patients remain conscious during the procedure, potentially causing specific anxieties and fears. the use of a stress ball is a non-pharmacological method that effectively distracts individuals consciously focusing on stimuli. this study is expected to be a randomized controlled trial, using convenience sampling to select patients receiving local anesthesia. they will be divided into two groups through computer-generated random number sequences: the stress ball group and the control group. the research aims to alleviate anxiety and pain levels in outpatient surgery patients receiving local anesthesia, with the goal of improving patients' postoperative mental health and quality of care.


Eligibility criteria:
inclusion criteria: - 1. those who are over 18 years old, have clear consciousness and can communicate in chinese and taiwanese hakka. 2. patients undergoing outpatient surgery under local anesthesia. exclusion criteria: * unable to cooperate

Keywords: anxiety stress ball ambulatory surgery
exercise and breast cancer related lymphedema: influence of muscle group and sequence on volume change in swollen and normal arms

Conditions: Breast Cancer; Lymphedema

Summary: arm exercise influences arm volume and symptoms in breast cancer related lymphedema.


Eligibility criteria:
inclusion criteria: * unilateral arm lymphedema as a result of breast cancer treatment * completion of breast cancer treatments * arm lymphedema onset 3 months or more after surgery and persistent for at least 6 months * in the maintenance phase of lymphedema treatment exclusion criteria: * women with recurrent cancer * intercurrent diseases affecting the swollen arm * lack of understanding of the hebrew language

Keywords: arm lymphedema breast cancer exercise breast cancer related lymphedema
implementing continuous glucose monitoring in primary care for patients with diabetes

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Continuous Glucose Monitoring

Summary: the overarching goal of this study is to decrease disparities and increase access to continuous glucose monitoring (cgm) for patients with diabetes, regardless of where people receive their diabetes care. this study aims to evaluate the effectiveness of three implementation strategies for cgm in primary care practices in an efficient, sustainable, and scalable fashion. the investigators will also perform economic analysis of the implementation strategies. this 3-year study will compare practices that implement cgm with (a) an evidence-based educational module only, (b) an educational module plus practice facilitation support, or (c) a virtual cgm initiation clinic for patients. there will be up to 30 practices in each group for a possible total of 90 primary care practices. the investigators expect to enroll up to 500 patient participants across these 90 practices and to compare outcomes among patients from each study arm. this comparison will help investigators to understand the different implementation strategies and their ability to help primary care practice adopt, implement, and maintain cgm for their patients. the information the investigators collect will also help to understand how patients in these primary care practices experience initiation and use of cgm. the results will help to develop strategies and tools to train more primary care practices to offer cgm more widely to patients for whom it is recommended, especially for those where access to specialty care is limited.


Eligibility criteria:
inclusion criteria: * between ages of 18 and 89 years * has diagnosis of type 1 diabetes or type 2 diabetes * recommended by primary care clinician to use continuous glucose monitoring to manage diabetes * ability to read or speak english or spanish exclusion criteria: * pregnant women * younger than 18 years of age * older than 89 years of age
evolution of bone mineral density (bmd) in patients with lymphoma undergoing chemotherapy

Conditions: Lymphoma; Osteoporosis

Summary: the purpose of this study is to assess changes of bone mineral density (bmd) at 12 months during the therapeutic management of patients with lymphoma.


Eligibility criteria:
inclusion criteria: * subjects aged 18 to 80 with lymphoma, * histological diagnosis of hodgkin's lymphoma (hl) or non-hodgkin lymphoma (nhl) of follicular or aggressive (large cell or other), * patients who have not yet started their chemotherapy or who have started for less than a month * patient has signed informed consent. exclusion criteria: * pathological fractures at the time of initial diagnosis of lymphoma, * compression of neurological epidural, * patients receiving treatment for osteoporosis (including bisphosphonates, selective modulators of estrogen receptor, calcitonin and parathyroid hormone teriparatide). * discovery of osteoporosis or osteopenia fracture during the initial evaluation requiring the establishment of an osteoporosis treatment, * radiotherapy to the lumbar spine or hip studied, * location of bone lymphoma in the lumbar spine or hip studied, * history of disorders affecting bone metabolism (prostate cancer with androgen, stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...) * a person incapable of giving consent personally, * pregnant or breastfeeding women, * protected person (under guardianship) * patient not affiliated with a social security system.

Keywords: lymphoma osteoporosis chemotherapy patient with
drug-drug interaction study between hec74647pa capsule and hec110114 tablets in healthy subjects

Conditions: Chronic Hepatitis C

Summary: the purpose of this study is to evaluate the drug-drug-interaction (ddi), pharmacokinetics (pk) and tolerability of hec74647 combined with hec110114 in healthy subjects

this is a 2-part study with each part is an open-label study in healthy adult subjects. total 28 subjects will be enrolled into the study and divided into 2 part (part a and part b), 14 subjects in each part. with each part, the subject will be receive study drug per the defined treatment periods of day 1\~7 and day 13\~19.

Eligibility criteria:
inclusion criteria: * sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions. * be able to complete the study according to the trail protocol. * subjects (including partners) have no pregnancy plan within 3 months after the last dose of study drug and voluntarily take effective contraceptive measures. * male subjects and must be 18 to 45 years of age inclusive. * body weight ≥ 50 kg and body mass index（bmi）between 18 and 28 kg / m2, inclusive. * physical examination and vital signs without clinically significant abnormalities. exclusion criteria: * use of \>5 cigarettes per day during the past 3 months. * known history of allergy to study drugs，or allergies constitution ( multiple drug and food allergies). * history of alcohol abuse (14 units of alcohol per week: 1 unit = 285 ml of beer, or 25 ml of spirits or 100 ml of wine). * donation or loss of blood over 450 ml within 3 months prior to screening. * 12-lead ecg with clinically significant. * positive for viral hepatitis (including hepatitis b and c), hiv and syphilis. * subjects deemed unsuitable by the investigator for any other reason.
pharmacokinetic, pharmacodynamic and tolerability study of otamixaban in patients with mild, moderate and severe renal impairment

Conditions: Renal Impairment

Summary: primary objective: * to study effect of mild, moderate and severe renal impairment on the pharmacokinetics of otamixaban. secondary objective: * to assess the pharmacodynamic effects of otamixaban on subjects with mild, moderate and severe renal impairment and in matched subjects with normal renal function.

the study period for one subject is broken down as follows: * 2 to 28 days of screening, * 1 day of treatment, * 8 to 11 days of follow-up after start of infusion. there are 5 days in the unit starting the day before the start of infusion.

Eligibility criteria:
inclusion criteria: * subject with renal impairment: * mild, moderate or severe renal impairment defined as creatinine clearance (crcl) from 50 to 80, 30 to 50 and \< 30 ml/min respectively, based on the cockcroft-gault formula, * body weight between 50.0 kg and 115.0 kg inclusive if male, between 40.0 kg and 95.0 kg inclusive if female, body mass index between 18.0 and 34.9 kg/m2 inclusive. * stable chronic renal impairment as defined by cockcroft-gault formula, * vital signs, cardiac function and laboratory parameters within the acceptable range. * or matched subject (by age, gender and body weight) with normal renal function (defined as crcl \>80 ml/min) and certified as healthy by physical examination, medical history and laboratory findings. * if female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal. exclusion criteria: * uncontrolled clinically relevant cardiovascular, pulmonary, gastro-intestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female) or infectious disease, or signs of acute illness. * active hepatitis, hepatic insufficiency. * acute renal failure, nephrotic syndrome. * history of or current hematuria of urologic origin. * subject requiring dialysis during the study. * history or presence of drug or alcohol abuse within two years before inclusion. * smoking more than 15 cigarettes or equivalent per day. * any significant change in chronic treatment medication within 14-days before inclusion. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
drug-induced sleep endoscopy for upper airway evaluation in obstructive sleep apnea

Conditions: Sleep Apnea, Obstructive

Summary: prospective, interventional cohort study of drug-induced sleep endoscopy (dise) to evaluate the upper airway in a cohort of obstructive sleep apnea (osa) surgical patients. this study has investigated the reliability of this technique, demonstrating moderate-substantial interrater and test-retest reliability. this research has also compared dise findings to those of the lateral cephalogram x-ray and examined dise findings in individuals who have not responded to previous sleep apnea surgery. these papers have been published and available through pubmed. additional research is ongoing, with examination of dise findings, comparison to other evaluation techniques, and the association between dise findings and surgical outcomes.


Eligibility criteria:
inclusion criteria: * adult patients with osa considering surgical treatment exclusion criteria: * minors * pregnant women * patients unable to provide informed consent in english themselves * prisoners * allergy to propofol, soybean oil, egg lecithin or glycerol * other contraindication to use of propofol (decision of anesthesiologist or otolaryngologist.)

Keywords: obstructive sleep apnea propofol sleep endoscopy
effect of duramesh™ on hernia formation after ileostomy closure, randomized controlled trial

Conditions: Incisional Hernia; Ileostomy - Stoma

Summary: diverting ileostomy is frequently utilized to protect high-risk anastomoses, though it is not shown to reduce the leak rate it may reduce the severe consequences of an anastomotic leak. ileostomy will be reversed with restoration of continuity in majority of patients. stoma site incisional hernias after ileostomy closure are complex hernias that can be associated with abdominal pain, discomfort, and a diminished quality of life. duramesh™ non-absorbable polypropylene suture is a hollow core, microporous, cylindrical suture made off in polypropylene filaments that are loosely braided and bonded to each other with heat and pressure. the aim of this study is to evaluate duramesh™ suture vs standard closure on rates of hernia formation after ileostomy closure.


Eligibility criteria:
inclusion criteria: * • patients undergoing ileostomy closure after surgery for cancer all patients with a stoma (independent of diagnosis) * age 18 or greater * surgical oncology patient where routine radiologic surveillance for malignancy is planned * patient accepts participation and gives informed consent exclusion criteria: * • pregnancy * prior mesh hernia repair at laparotomy site * life expectancy less than 1 years * patient is unable / unwilling to provide informed consent * patient is unable to comply with the protocol or proposed follow-up visits * patient is enrolled in another hernia study * non-english-speaking participants * data from children will not analyzed in this study. * cognitively impaired adults: data from cognitively impaired adults will not analyzed in this study. * adults unable to consent: data from adults unable to consent will not analyzed in this study.

Keywords: duramesh,
anlotinib combined with stupp for mgmt nonmethylated glioblastoma

Conditions: MGMT-Unmethylated Glioblastoma

Summary: the purpose of this study is to test the efficacy and safety of anlotinib in combination with stupp regimen for mgmt promoter nonmethylated glioblastoma.

for mgmt unmethylated glioblastoma patients undergoing stupp regimen adjuvant therapy, during adjuvant chemotherapy, concurrent with anti-angiogenesis targeted therapy(anlotinib capsule,d1-14).

Eligibility criteria:
inclusion criteria: 1. aged 18-70 years, 2. histologically proven diagnosis of glioblastoma (who grade iv), 3. have received standard stupp treatment plan, 4. gross resection or partial resection of the tumor (confirmed by mri)\> 50%, 5. the pathological tissue specimens are detected as mgmt unmethylated,6.karnofsky performance status ≥ 60, 6. no previous radiotherapy, chemotherapy, immunotherapy or biotherapy 7.adequate bone marrow function: hemoglobin ≥ 100g/l，platelets ≥ 80×109/l，absolute neutrophil count (anc) ≥ 1.5×109/l 8.adequate renal function: serum creatinine ≤ 1.25 x unl (upper normal limit) or creatinine clearance ≥ 60 ml/min 9.adequate hepatic function: serum bilirubin ≤ 1.5 x unl, ast and alt ≤ 2.5 x unl，alp≤5x unl 10.for females of child-bearing potential, negative serum pregnancy test within 14 days prior to registration. women of childbearing potential and male participants must practice adequate contraception during participation in the study and within 8 weeks after the last administration of the drug 11.able to provide written informed consent exclusion criteria: 1. recurrent or multiple malignant gliomas 2. subtentorial glioblastoma or metastatic lesions outside the skull 3. have received radiotherapy, chemotherapy or other anti-tumor drugs for the disease before surgery 4. previously received radiation therapy for the head and neck cancer 5. have received any antibody treatment before 6. contraindication of radiotherapy and chemotherapy defined as follows: acute bacterial or fungal infection，unstable angina and/or congestive heart failure within the last 6 months，co-morbidity with immunosuppressive therapy 7. evidence of bleeding diathesis or coagulopathy 8. prior invasive malignancy (except for non-melanomatous skin cancer or carcinoma in situ of cervix)
a restylane treatment algorithm approach for participants with appearance of insufficient bone structure in the lower face alone or in combination with facial soft tissue deficiencies

Conditions: Chin Augmentation

Summary: the study's main purpose is to evaluate the overall aesthetic improvement of the treated areas by treatment group, as assessed by the investigator.


Eligibility criteria:
inclusion criteria: * participant is willing to comply with the requirements of the study including being photographed, following post-treatment care instructions, attending all study visits and providing a signed written informed consent. * males or non-pregnant, non-breastfeeding females, over the age of 18. * intent to receive treatment for temporary augmentation in the chin region. exclusion criteria: * known/previous allergy or hypersensitivity to any injectable hyaluronic acid (ha) gel or to gram positive bacterial proteins and/or local anesthetics, e.g., lidocaine or other amide-type anesthetics * previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions. * previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from the lower orbital rim. * any previous aesthetic procedures or implants. * use of concomitant medication that have the potential to prolong bleeding times such as anticoagulants or inhibitors of platelet aggregation. * participation in any other interventional clinical study within 30 days (about 4 and a half weeks) before baseline. * women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.

Keywords: lower face mid face